首页> 外文OA文献 >P3844Effectiveness, safety, and composite clinical outcomes of apixaban, dabigatran, rivaroxaban, relative to warfarin in non-valvular atrial fibrillation patients in the US Medicare population

【2h】

P3844Effectiveness, safety, and composite clinical outcomes of apixaban, dabigatran, rivaroxaban, relative to warfarin in non-valvular atrial fibrillation patients in the US Medicare population

机译：P3844紫杉醇，Dabigatran，Rivaroxaban的P3844效应，安全性和复合临床结果，相对于美国医疗保险人群的非瓣膜心房颤动患者的华法林

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
相似文献
相关主题

著录项

作者
A Amin; A Keshishian; Q Zhang; O Dina; A Dhamane; A Nadkarni; E Carda; X Liu; L Rosenblatt; O Baser; C Baker;
展开▼
作者单位

展开▼
年度 2018
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. Risk of stroke/systemic embolism, major bleeding and associated costs in non-valvular atrial fibrillation patients who initiated apixaban, dabigatran or rivaroxaban compared with warfarin in the United States Medicare population [J] . Amin Alpesh, Keshishian Allison, Trocio Jeffrey, Current medical research and opinion . 2017,第9期

机译：与美国医疗保险人口的华法林相比，中风/全身栓塞患者的中风/全身栓塞患者的严重出血和相关成本
2. Relative efficacy and safety of non-Vitamin K oral anticoagulants for non-valvular atrial fibrillation: Network meta-analysis comparing apixaban, dabigatran, rivaroxaban and edoxaban in three patient subgroups [J] . Lip Gregory Y. H., Mitchell Stephen A., Liu Xianchen, International Journal of Cardiology . 2016,第Null期

机译：非维生素K口服抗凝剂对非瓣膜性心房颤动的相对疗效和安全性：网络荟萃分析比较了三个患者亚组中的apixaban，dabigatran，rivaroxaban和edoxaban
3. Bleeding risk of apixaban, dabigatran, and low-dose rivaroxaban compared with warfarin in Japanese patients with non-valvular atrial fibrillation: a propensity matched analysis of administrative claims data [J] . Kohsaka Shun, Murata Tatsunori, Izumi Naoko, Current medical research and opinion . 2017,第11期

机译：与日本非瓣膜心房颤动的日本患者的华法林相比，Apixaban，Dabigatran和低剂量Rivaroxaban的出血风险：行政权利要求的倾向匹配分析
4. CLINICAL OUTCOME OF 4-PULMONARY VEIN ISOLATION IN PATIENTS WITH PERSISTENT ATRIAL FIBRILLATION [C] . SEIICHIRO MATSU International Congress on Electrocardiology . 2005

机译：持续性心房颤动患者4肺静脉分离的临床结果
5. Cost-effectiveness of apixaban, dabigatran, rivaroxaban, and warfarin for the prevention of stroke prophylaxis in atrial fibrillation. [D] . Harrington, Amanda. 2012

机译：阿哌沙班，达比加群，利伐沙班和华法林预防房颤预防中风的成本效益。
6. Dabigatran rivaroxaban and apixaban are superior to warfarin in Asian patients with non-valvular atrial fibrillation: An updated meta-analysis [O] . Wei-Jia Li, Paraschos Archontakis-Barakakis, Leonidas Palaiodimos, 2021

机译：DabigatranRivaroxaban和Apixaban优于亚洲非瓣膜心房颤动患者的华法林：更新的荟萃分析
7. Risk of stroke/systemic embolism, major bleeding and associated costs in non-valvular atrial fibrillation patients who initiated apixaban, dabigatran or rivaroxaban compared with warfarin in the United States Medicare population [O] . Alpesh Amin, Allison Keshishian, Jeffrey Trocio, 2017

机译：中风/全身栓塞的风险，非瓣膜心房颤动患者中的主要出血和相关成本，他在美国Medicare人口中与华法林相比的疟原虫，Dabigatran或Rivaroxaban相比

P3844Effectiveness, safety, and composite clinical outcomes of apixaban, dabigatran, rivaroxaban, relative to warfarin in non-valvular atrial fibrillation patients in the US Medicare population

著录项

相似文献

相关主题

期刊订阅